Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track TYRA with free AI briefings, catalyst countdowns, and dilution alerts.

TYRA · Tyra Biosciences, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$700.5M Cash on Hand
66.4mo Cash Runway
Follow TYRA by email Get an email when TYRA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about TYRA, unsubscribe in one click. Privacy

📣 What TYRA Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Dabogratinib (TYRA-300) Low Grade Upper Tract Urothelial Carcinoma Phase 2 · NCT07265947 Recruiting
Phase 1 Part A - dose escalation TYRA-200 taken… Locally Advanced Cholangiocarcinoma Phase 1 · NCT06160752 Active not recruiting
Phase 1 Part B - dose expansion TYRA-200 taken… Locally Advanced Cholangiocarcinoma Phase 1 · NCT06160752 Active not recruiting
FGFR3/4 Inhibitor TYRA-430 Metastatic Hepatocellular Carcinoma Phase 1 · NCT06915753 Recruiting

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

TYRA holds $700.5M in cash and short-term investments (as of Sep 30, 2026) and burns about $31.6M/quarter from operations, an estimated runway of 66.4 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 24 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when TYRA files for a raise →

👥 Who Owns TYRA

Insiders 28.5% Other 5%+ holders 15.4% Institutions (233 holders) 56.1% Public and other holders 0%
HolderTypeShares% of sharesAs of
RA CAPITAL MANAGEMENT, L.P.
Director, 10% owner · +11.63M options
Insider 14,130,492 20.45% 2026-09-15
FMR LLC Institution (13G, 5%+) 7,747,648 11.22% 2026-03-31
BVF PARTNERS L P/IL Institution (13G, 5%+) 4,215,886 6.10% 2026-09-14
JANUS HENDERSON GROUP PLC Institution (13G, 5%+) 3,890,589 5.63% 2026-03-31
Robert J More
Director · +13,160 options
Insider 3,823,425 5.53% 2025-12-19
Dapice Joshua J. 5%+ holder (13G) 3,580,818 5.18% 2026-03-31
Nextech VI Oncology SCSp 5%+ holder (13G) 3,553,585 5.14% 2026-06-30
Paradigm BioCapital Advisors LP 5%+ holder (13G) 3,473,453 5.03% 2026-09-10
Todd Harris
President and CEO, Director · +835,000 options
Insider 1,438,495 2.08% 2026-09-15
Daniel Bensen
Chief Discovery Officer · +170,000 options
Insider 146,981 0.21% 2026-02-12
Alan Fuhrman
Chief Financial Officer · +237,000 options
Insider 37,115 0.05% 2026-09-15
Gilla Kaplan
Director
Insider 28,231 0.04% 2026-03-25

Share count 69,082,747 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full TYRA picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for TYRA and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.